Mytolac (Lanreotide Acetate)

Lanreotide acetate, the active ingredient in Mytolac, is a somatostatin analog presented as a subcutaneous formulation for injection use. It is employed in the management of hormone‑secreting disorders such as acromegaly and certain neuroendocrine tumors, acting to suppress excess hormone release in adult patients.

GNH USA supplies Mytolac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mytolac, a somatostatin analog, is used to control hormone‑driven conditions within the endocrine and neuroendocrine disease spectrum.

Acromegaly: reduces excess growth hormone production and helps normalize insulin‑like growth factor‑1 levels. Neuroendocrine tumors: inhibits tumor‑related hormone secretion, improving symptom control. Carcinoid syndrome: diminishes flushing and diarrhoea by blocking serotonin and other vasoactive substances.

Mytolac may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Injection site pain or erythema. - Nausea or vomiting. - Diarrhoea or abdominal discomfort. - Headache. - Hyperglycaemia or altered glucose tolerance. - Fatigue.

Serious or Rare Side Effects: - Gallstone formation or biliary colic. - Acute pancreatitis. - Severe allergic reactions, including anaphylaxis. - Cardiac arrhythmias. - Pituitary apoplexy in patients with pre‑existing adenomas. - Severe hyperglycaemia requiring medical intervention.

Before initiating Mytolac, clinicians should consider several safety measures.

Monitor glucose levels: patients may develop hyperglycaemia, especially those with diabetes. Assess gallbladder status: prolonged therapy can increase the risk of gallstones. Screen for pancreatitis: watch for persistent abdominal pain or elevated enzymes. Evaluate cardiac function: rare arrhythmias have been reported. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mytolac can interact with other agents that affect hormone levels or gastrointestinal motility.

Major Interactions (Avoid): - Concomitant use with other somatostatin analogues (e.g., octreotide) may cause additive hormonal suppression. - Strong CYP450 inhibitors that alter peptide metabolism, potentially increasing exposure. - Antidiabetic drugs: risk of hypoglycaemia if glucose control improves markedly.

Moderate Interactions (Monitor Closely): - Oral glucose tolerance agents: dose adjustments may be needed. - Medications that delay gastric emptying (e.g., anticholinergics) could exacerbate gastrointestinal side effects. - Warfarin: monitor INR as rare reports suggest altered coagulation parameters.